Alnylam Pharmaceuticals
ALNY
#626
Rank
A$50.32 B
Marketcap
$390.17
Share price
1.06%
Change (1 day)
40.35%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -A$0.28 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are A$2.09 Billion. In 2023 the company made an earning of -A$0.5 Billion, an increase over its 2022 earnings that were of -A$1.54 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -A$0.28 Billion-44.56%
2023 -A$0.5 Billion-67.84%
2022 -A$1.54 Billion36.93%
2021 -A$1.13 Billion-8.04%
2020 -A$1.23 Billion-15.66%
2019 -A$1.45 Billion12.23%
2018 -A$1.29 Billion62.91%
2017 -A$0.8 Billion17.78%
2016 -A$0.68 Billion43.44%
2015 -A$0.47 Billion60.69%
2014 -A$0.3 Billion98.2%
2013 -A$0.15 Billion
2011 -A$86.74 Million27.48%
2010 -A$68.05 Million-10.92%
2009 -A$76.39 Million95.77%
2008 -A$39.02 Million
2006 -A$62.51 Million-9.13%
2005 -A$68.79 Million34.74%
2004 -A$51.06 Million36.79%
2003 -A$37.33 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-A$0.92 Billion 210.42%๐Ÿ‡บ๐Ÿ‡ธ USA
A$7.86 B-2,759.15%๐Ÿ‡บ๐Ÿ‡ธ USA
A$0.20 B-169.24%๐Ÿ‡บ๐Ÿ‡ธ USA
-A$0.19 Billion-36.94%๐Ÿ‡บ๐Ÿ‡ธ USA
-A$65.46 Million-77.86%๐Ÿ‡บ๐Ÿ‡ธ USA
A$20.14 B-6,912.96%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
A$11.72 B-4,063.98%๐Ÿ‡ซ๐Ÿ‡ท France
A$0.66 B-324.74%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel